Wat is de prijs voor Scilex Holding Company (SCLX)

Het prijs van Scilex Holding Company (SCLX) is $5.61

Wat is de marktkapitalisatie voor Scilex Holding Company (SCLX)

Marktkapitalisatie voorScilex Holding Company (SCLX) is $47.65M

Scilex Holding Company (SCLX) Aandelensplitsingen

Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.

Jaar	Splitsing	Vermenigvuldiging	Cumulatieve vermenigvuldiging
Niet genoeg gegevens voor de verstrekte datums.

Jaar

Splitsing

Vermenigvuldiging

Cumulatieve vermenigvuldiging

Niet genoeg gegevens voor de verstrekte datums.

Bedrijf	Aantal aandelen splitsingen	Cumulatieve vermenigvuldiging	Land
Eli Lilly and Company LLY.US	4	x15	US
Johnson & Johnson JNJ.US	7	x432	US
AbbVie Inc. ABBV.US	0	-	US
Roche Holding AG RO.SW	2	x10000	CH
Merck & Co., Inc. MRK.US	7	x226	US

Bedrijf

Aantal aandelen splitsingen

Cumulatieve vermenigvuldiging

Land